Moneycontrol PRO
dr reddys labs
Jump to
  • Buy Dr Reddy’s Labs; target of Rs 5180: Motilal Oswal Nov 01, 2022 07:05 PM IST

    Buy Dr Reddy’s Labs; target of Rs 5180: Motilal Oswal

    Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5180 in its research report dated October 29, 2022.

  • Dr Reddys Labs Consolidated September 2022 Net Sales at Rs 6,331.80 crore, up 9.42% Y-o-Y Oct 28, 2022 11:22 PM IST

    Dr Reddys Labs Consolidated September 2022 Net Sales at Rs 6,331.80 crore, up 9.42% Y-o-Y

  • Dr Reddys Labs Standalone September 2022 Net Sales at Rs 4,880.30 crore, up 27.64% Y-o-Y Oct 28, 2022 11:11 PM IST

    Dr Reddys Labs Standalone September 2022 Net Sales at Rs 4,880.30 crore, up 27.64% Y-o-Y

  • Buy Dr Reddy’s Labs; target of Rs 5000: Motilal Oswal Jul 30, 2022 10:43 PM IST

    Buy Dr Reddy’s Labs; target of Rs 5000: Motilal Oswal

    Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 29, 2022.

  • Dr Reddys Labs Consolidated June 2022 Net Sales at Rs 5,232.90 crore, up 5.82% Y-o-Y Jul 28, 2022 10:22 PM IST

    Dr Reddys Labs Consolidated June 2022 Net Sales at Rs 5,232.90 crore, up 5.82% Y-o-Y

  • Dr Reddys Labs Standalone June 2022 Net Sales at Rs 3,630.60 crore, up 5.74% Y-o-Y Jul 28, 2022 10:11 PM IST

    Dr Reddys Labs Standalone June 2022 Net Sales at Rs 3,630.60 crore, up 5.74% Y-o-Y

  • Dr Reddy’s Labs Q1 Result | Profit jumps 108% YoY to Rs 1,188 crore; revenue grows 6% Jul 28, 2022 04:26 PM IST

    Dr Reddy’s Labs Q1 Result | Profit jumps 108% YoY to Rs 1,188 crore; revenue grows 6%

    The growth was aided by strong traction in the company’s US business which helped the company negate the impact of the high base of last year in its Indian operations due to COVID.

  • Buy Dr Reddy’s Labs; target of Rs 4800: Motilal Oswal May 21, 2022 07:52 PM IST

    Buy Dr Reddy’s Labs; target of Rs 4800: Motilal Oswal

    Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 4800 in its research report dated May 20, 2022.

  • Dr Reddys Labs Consolidated March 2022 Net Sales at Rs 5,474.90 crore, up 14.82% Y-o-Y May 19, 2022 04:00 PM IST

    Dr Reddys Labs Consolidated March 2022 Net Sales at Rs 5,474.90 crore, up 14.82% Y-o-Y

  • Dr Reddys Labs Standalone March 2022 Net Sales at Rs 3,668.70 crore, up 9.49% Y-o-Y May 19, 2022 04:00 PM IST

    Dr Reddys Labs Standalone March 2022 Net Sales at Rs 3,668.70 crore, up 9.49% Y-o-Y

  • Pharma companies turn to acquisitions to build scale, gain an edge Mar 14, 2022 08:50 AM IST

    Pharma companies turn to acquisitions to build scale, gain an edge

    Pharma companies are reorganising themselves, by focusing on select products lines, regions and exiting non-core assets

  • Novartis India transfers sales and distribution to Dr Reddy’s Labs, to axe 400 employees Feb 11, 2022 10:23 PM IST

    Novartis India transfers sales and distribution to Dr Reddy’s Labs, to axe 400 employees

    Interestingly, Novartis which hired over 1,600 employees across divisions in India since January 2020 says it is planning to continue the hiring programme in 2022.

  • Buy Dr Reddy’s Labs; target of Rs 5160: Motilal Oswal Feb 01, 2022 09:52 PM IST

    Buy Dr Reddy’s Labs; target of Rs 5160: Motilal Oswal

    Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5160 in its research report dated January 29, 2022.

  • Dr Reddys Labs Consolidated December 2021 Net Sales at Rs 5,338.30 crore, up 8.02% Y-o-Y Feb 01, 2022 10:11 AM IST

    Dr Reddys Labs Consolidated December 2021 Net Sales at Rs 5,338.30 crore, up 8.02% Y-o-Y

  • Dr Reddys Labs Standalone December 2021 Net Sales at Rs 3,479.60 crore, up 2.09% Y-o-Y Feb 01, 2022 09:22 AM IST

    Dr Reddys Labs Standalone December 2021 Net Sales at Rs 3,479.60 crore, up 2.09% Y-o-Y

  • Hold Dr Reddy's Labs; target of Rs 5105: Edelweiss Securities Dec 06, 2021 03:26 PM IST

    Hold Dr Reddy's Labs; target of Rs 5105: Edelweiss Securities

    Edelweiss Securities recommended hold rating on Dr Reddy's Labs with a target price of Rs 5105 in its research report dated December 03, 2021.

  • Dr Reddys Labs Standalone September 2021 Net Sales at Rs 3,823.40 crore, up 14.27% Y-o-Y Nov 09, 2021 08:46 AM IST

    Dr Reddys Labs Standalone September 2021 Net Sales at Rs 3,823.40 crore, up 14.27% Y-o-Y

  • Dr Reddys Labs Consolidated September 2021 Net Sales at Rs 5,786.90 crore, up 17.84% Y-o-Y Nov 08, 2021 07:11 PM IST

    Dr Reddys Labs Consolidated September 2021 Net Sales at Rs 5,786.90 crore, up 17.84% Y-o-Y

  • Dr Reddys Labs Standalone September 2021 Net Sales at Rs 3,823.40 crore, up 14.27% Y-o-Y Nov 08, 2021 07:00 PM IST

    Dr Reddys Labs Standalone September 2021 Net Sales at Rs 3,823.40 crore, up 14.27% Y-o-Y

  • Buy Dr Reddy’s Labs; target of Rs 5470: Motilal Oswal Nov 03, 2021 01:35 PM IST

    Buy Dr Reddy’s Labs; target of Rs 5470: Motilal Oswal

    Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5470 in its research report dated October 30, 2021.

  • Dr Reddys Labs Consolidated June 2021 Net Sales at Rs 4,945.10 crore, up 11.72% Y-o-Y Jul 27, 2021 07:22 PM IST

    Dr Reddys Labs Consolidated June 2021 Net Sales at Rs 4,945.10 crore, up 11.72% Y-o-Y

  • Dr Reddys Labs Standalone June 2021 Net Sales at Rs 3,433.50 crore, up 5.83% Y-o-Y Jul 27, 2021 07:11 PM IST

    Dr Reddys Labs Standalone June 2021 Net Sales at Rs 3,433.50 crore, up 5.83% Y-o-Y

  • Dr Reddy's Labs share price gains over launch of COVID-19 treatment drug Jun 28, 2021 10:15 AM IST

    Dr Reddy's Labs share price gains over launch of COVID-19 treatment drug

    In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India, the company said in an exchange filing.

  • COVID-19 vaccine | Sputnik V's pilot soft launch scaled up to test cold storage facilities, logistics: Dr Reddy's Jun 13, 2021 08:56 PM IST

    COVID-19 vaccine | Sputnik V's pilot soft launch scaled up to test cold storage facilities, logistics: Dr Reddy's

    DRL said the pilot launch would help test cold storage and other logistical arrangements before the vaccine's commercial launch.

  • Dr Reddys Labs Consolidated March 2021 Net Sales at Rs 4,768.20 crore, up 7.18% Y-o-Y May 14, 2021 08:11 PM IST

    Dr Reddys Labs Consolidated March 2021 Net Sales at Rs 4,768.20 crore, up 7.18% Y-o-Y